Simon Carding

Prof. Simon Carding

orcid

Research Focus & Metrics

Academic Career Length

43Years (1984-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2007 in The Lancet
Verified
Journal Article
Closed access
DBDaniel C Baumgart
Daniel C Baumgart
SCSimon Carding
Simon Carding

2 February 2015 in Microbial Ecology in Health and Disease
Verified
Journal Article
Open access
PDF file
SCSimon Carding
Simon Carding
Kristin VerbekeKristin Verbeke
Kristin Verbeke
DVDaniel T. Vipond
Daniel T. Vipond
BCBernard Corfe
Bernard Corfe
LOLauren Owen
Lauren Owen
Dysbiosis of the gut microbiota in disease

1 May 2002 in Nature Reviews Immunology
Verified
Journal Article
Closed access
SCSimon Carding
Simon Carding
PEPaul J. Egan
Paul J. Egan

1 August 2019 in Gut Microbes
Verified
Journal Article
Open access
APAimée Parker
Aimée Parker
SFSonia Fonseca
Sonia Fonseca
SCSimon Carding
Simon Carding
The human gastrointestinal (gut) microbiota comprises diverse and dynamic populations of bacteria, archaea, viruses, fungi, and protozoa, coexisting in a mutualistic relationship with the host. When intestinal homeostasis is perturbed, the function of the gastrointestinal tract and other organ systems, including the brain, can be compromised. The gut microbiota is proposed to contribute to blood-brain barrier disruption and the pathogenesis of neurodegenerative diseases. While progress is being made, a better understanding of interactions between gut microbes and host cells, and the impact these have on signaling from gut to brain is now required. In this review, we summarise current evidence of the impact gut microbes and their metabolites have on blood-brain barrier integrity and brain function, and the communication networks between the gastrointestinal tract and brain, which they may modulate. We also discuss the potential of microbiota modulation strategies as therapeutic tools for promoting and restoring brain health.

29 April 2022 in Microbiome
Verified
Journal Article
Open access
PDF file
APAimée Parker
Aimée Parker
SRStefano Romano
Stefano Romano
RARebecca Ansorge
Rebecca Ansorge
AAAsmaa Aboelnour
Asmaa Aboelnour
GGGwenaelle Le Gall
Gwenaelle Le Gall
SCSimon Carding
Simon Carding
Background: Altered intestinal microbiota composition in later life is associated with inflammaging, declining tissue function, and increased susceptibility to age-associated chronic diseases, including neurodegenerative dementias. Here, we tested the hypothesis that manipulating the intestinal microbiota influences the development of major comorbidities associated with aging and, in particular, inflammation affecting the brain and retina. Methods: Using fecal microbiota transplantation, we exchanged the intestinal microbiota of young (3 months), old (18 months), and aged (24 months) mice. Whole metagenomic shotgun sequencing and metabolomics were used to develop a custom analysis workflow, to analyze the changes in gut microbiota composition and metabolic potential. Effects of age and microbiota transfer on the gut barrier, retina, and brain were assessed using protein assays, immunohistology, and behavioral testing. Results: We show that microbiota composition profiles and key species enriched in young or aged mice are successfully transferred by FMT between young and aged mice and that FMT modulates resulting metabolic pathway profiles. The transfer of aged donor microbiota into young mice accelerates age-associated central nervous system (CNS) inflammation, retinal inflammation, and cytokine signaling and promotes loss of key functional protein in the eye, effects which are coincident with increased intestinal barrier permeability. Conversely, these detrimental effects can be reversed by the transfer of young donor microbiota. Conclusions: These findings demonstrate that the aging gut microbiota drives detrimental changes in the gut–brain and gut–retina axes suggesting that microbial modulation may be of therapeutic benefit in preventing inflammation-related tissue decline in later life. Graphical

9 January 2018 in The EMBO Journal
Verified
Journal Article
Open access
PDF file
KFKatherine Fletcher
Katherine Fletcher
RURachel Ulferts
Rachel Ulferts
EJElise Jacquin
Elise Jacquin
TVTalitha Veith
Talitha Veith
NGNoor Gammoh
Noor Gammoh
OFOliver Florey
Oliver Florey
A hallmark of macroautophagy is the covalent lipidation of LC3 and insertion into the double‐membrane phagophore, which is driven by the ATG16L1/ATG5‐ATG12 complex. In contrast, non‐canonical autophagy is a pathway through which LC3 is lipidated and inserted into single membranes, particularly endolysosomal vacuoles during cell engulfment events such as LC3‐associated phagocytosis. Factors controlling the targeting of ATG16L1 to phagophores are dispensable for non‐canonical autophagy, for which the mechanism of ATG16L1 recruitment is unknown. Here we show that the WD repeat‐containing C‐terminal domain (WD40 CTD) of ATG16L1 is essential for LC3 recruitment to endolysosomal membranes during non‐canonical autophagy, but dispensable for canonical autophagy. Using this strategy to inhibit non‐canonical autophagy specifically, we show a reduction of MHC class II antigen presentation in dendritic cells from mice lacking the WD40 CTD. Further, we demonstrate activation of non‐canonical autophagy dependent on the WD40 CTD during influenza A virus infection. This suggests dependence on WD40 CTD distinguishes between macroautophagy and non‐canonical use of autophagy machinery.